US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

retatrutide mechanism · triple agonist pharmacology · research use only

How does retatrutide work? The triple-receptor mechanism explained.

The short answer: retatrutide (LY3437943) works by simultaneously activating three G-protein-coupled receptors that govern appetite, insulin secretion, and energy expenditure — the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. No prior approved obesity drug targets all three. The mechanism is formally described in the Phase 2 NEJM 2023 paper (Jastreboff AM et al., NEJM 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315): retatrutide is 'a single peptide conjugated to a fatty diacid moiety' with agonism across all three receptors, approximately 8.9× more potent than the endogenous GIP ligand at the human GIP receptor, and approximately 0.4× and 0.3× as potent as the endogenous ligands at GLP-1 and glucagon receptors respectively — a profile tuned to lead with strong GIP activity. The ~6-day half-life (enabled by the acyl modification) allows once-weekly subcutaneous dosing. This is a single-compound mechanism page, distinct from the fat-loss class overview. Retatrutide is an investigational compound; Titan's product is a research-use-only reagent, not for human or animal use. Not medical or dosing advice.

Retatrutide research reagent — $199.99 (in stock)Retatrutide dosage reference

GLP-1 receptor arm: appetite suppression and gastric slowing

GLP-1 (glucagon-like peptide-1) is an endogenous incretin secreted from intestinal L-cells in response to eating. GLP-1 receptor agonism produces satiety and reduces food intake by acting on hypothalamic appetite circuits and the vagus nerve; it also slows gastric emptying (prolonging post-meal fullness) and stimulates glucose-dependent insulin secretion while suppressing glucagon in hyperglycaemia. These are the effects established across the GLP-1 receptor agonist class (semaglutide, liraglutide) and are one of the three pathways retatrutide engages. In the triple-agonist design, GLP-1R agonism provides the appetite-reduction and glycaemic backbone.

Retatrutide vs semaglutide (GLP-1 mono-agonist) →

GIP receptor arm: the dominant potency arm in retatrutide

GIP (glucose-dependent insulinotropic polypeptide) is the main incretin in healthy individuals. As described in the NEJM 2023 paper, retatrutide is approximately 8.9× more potent than the endogenous GIP ligand at the human GIP receptor — making GIP receptor agonism the highest-potency arm. GIP receptor agonism augments insulin secretion in a glucose-dependent manner, enhances the insulin sensitivity of white adipose tissue and its lipid-buffering capacity, and is hypothesised to act centrally to potentiate GLP-1-induced appetite reduction. The strong GIP arm is the primary mechanistic differentiator from semaglutide (GLP-1-only) and is shared with tirzepatide, though retatrutide adds a glucagon arm tirzepatide lacks.

Retatrutide vs tirzepatide (GIP/GLP-1 dual agonist) →

Glucagon receptor arm: the energy-expenditure differentiator

The glucagon receptor (GCGR) arm is what distinguishes retatrutide from all prior approved obesity agents. Glucagon receptor agonism is studied for increasing energy expenditure via thermogenesis in brown adipose tissue — distinct from appetite reduction. A 2022 peer-reviewed review (Conceição-Furber, Coskun, Sloop & Samms, Eli Lilly researchers; Front. Endocrinol. 2022;13:868037, doi: 10.3389/fendo.2022.868037) reviewed evidence that glucagon receptor activation stimulates thermogenesis in brown adipose tissue in vitro, and that glucagon has been associated with enhanced metabolic rate in humans in prior studies. In retatrutide, the GCGR arm is the third pathway — adding an energy-expenditure component to appetite suppression (GLP-1/GIP). This is the mechanistic rationale for why the trial results exceeded dual-agonist benchmarks.

Peptides for fat loss: the class overview →

~6-day half-life: the acylation mechanism

Retatrutide achieves its approximately 6-day half-life through fatty diacid conjugation — an acyl chain attached to the peptide backbone. The NEJM 2023 paper states: 'The pharmacokinetics of retatrutide are considered dose-proportional; it has a half-life of approximately 6 days, which enables weekly administration.' The fatty diacid moiety promotes reversible binding to albumin in circulation, dramatically extending residence time compared to an unmodified peptide (which would clear in minutes). This is the same pharmacokinetic strategy used in semaglutide. For identity verification purposes, the acylated species has a distinct molecular mass from unmodified peptide and must be confirmed by mass spectrometry — a purity number alone does not confirm the acyl modification is present or correct.

Retatrutide half-life reference →

Phase 2 trial outcomes: what the mechanism produced

Mechanism is most meaningful alongside the human outcome data. In the Phase 2 randomised controlled trial (n=338, 48 weeks, Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315): least-squares mean weight change vs placebo was −24.2% (12 mg), −22.8% (8 mg), −17.1% (4 mg), and −8.7% (1 mg) vs −2.1% placebo at 48 weeks. At 24 weeks the 12-mg group had reached −17.5%. Weight reduction ≥5% occurred in 92% of participants at 4 mg and above. The dose-dependence across four dose levels (1, 4, 8, 12 mg) establishes a clear pharmacodynamic dose-response curve, consistent with receptor agonism. The most common adverse events were gastrointestinal (nausea, vomiting) — dose-related, mostly mild-to-moderate, characteristic of the GLP-1 receptor arm.

How long does retatrutide take to work →

Acylated identity: what COA verification actually means for retatrutide

Understanding the mechanism clarifies why identity verification matters for this specific compound. The ~6-day half-life — and the pharmacodynamic profile described in the NEJM paper — depends on the fatty diacid acylation being present, at the correct position, on the correct peptide sequence. An unmodified or mis-acylated sequence might still produce a high HPLC purity peak while having a completely different half-life and receptor-binding profile. Lot-matched ESI-MS identity confirmation verifies the molecular mass of the acylated species against expected values; HPLC purity confirms the major peak proportion. Titan supplies both in a lot-matched in-house release sheet on request. No third-party COA is claimed — the verifiable edge is a real, lot-matched in-house release sheet.

Lot COA checklist for acylated peptides →

The detail, in plain terms

Retatrutide mechanism, at a glance.

Points below summarise the pharmacology of retatrutide as described in the NEJM 2023 Phase 2 publication and supporting literature. This is a research reference for the single compound — not a class overview (see peptides-for-fat-loss for that). Research use only; not medical or dosing advice.

Compound name / identifier
Retatrutide; also LY3437943 (Eli Lilly internal designation). Single acylated peptide.
Receptor targets (triple agonist)
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R) + glucagon receptor (GCGR). All three are G-protein-coupled receptors involved in nutrient-stimulated hormone signalling.
GIP receptor potency
~8.9× more potent than endogenous GIP ligand at human GIPR. The highest-potency arm. (NEJM 2023 Methods.)
GLP-1 receptor potency
~0.4× as potent as endogenous GLP-1 ligand at human GLP-1R. Still produces meaningful receptor activation at clinical doses. (NEJM 2023 Methods.)
Glucagon receptor potency
~0.3× as potent as endogenous glucagon at human GCGR. Thermogenic / energy-expenditure arm. (NEJM 2023 Methods.)
Half-life
~6 days — achieved via fatty diacid acylation (albumin binding). Enables once-weekly SC dosing. (NEJM 2023.)
GLP-1 arm: what it does
Appetite suppression (central satiety), gastric emptying delay, glucose-dependent insulin secretion, glucagon suppression in hyperglycaemia.
GIP arm: what it does
Glucose-dependent insulin secretion; adipose-tissue lipid buffering + insulin sensitisation; central GLP-1 appetite potentiation (hypothesised). Dominant potency arm in retatrutide.
Glucagon arm: what it does
Energy expenditure via brown adipose tissue thermogenesis + resting metabolic rate enhancement — studied as the differentiating arm vs GLP-1/GIP dual agonists. (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037.)
Phase 2 weight change (48wk)
LS-mean: 12 mg −24.2%, 8 mg −22.8%, 4 mg −17.1%, 1 mg −8.7% vs placebo −2.1%. (Jastreboff et al., NEJM 2023, n=338.)
Regulatory / RUO status
Investigational — no FDA approval. Titan's product is a research-use-only reagent, not for human or animal use. No efficacy claim.
COA identity check
Acylated species: mass confirmed by ESI-MS (not purity alone). Titan: lot-matched in-house HPLC + ESI-MS identity sheet on request. No third-party COA claimed.

Questions researchers ask

Before you order.

How does retatrutide work?
Retatrutide (LY3437943) is a triple agonist: it simultaneously activates three G-protein-coupled receptors — the GIP receptor, the GLP-1 receptor, and the glucagon receptor. GLP-1 receptor agonism suppresses appetite and slows gastric emptying. GIP receptor agonism (the highest-potency arm, ~8.9× more potent than the endogenous GIP ligand) adds adipose insulin sensitisation and is hypothesised to potentiate GLP-1's central appetite effects. The glucagon receptor arm adds a thermogenic/energy-expenditure component via brown adipose tissue activation. This three-arm design is distinct from semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 only). The pharmacology is described in Jastreboff et al., NEJM 2023;389:514-526 (PMID 37366315). Research-use-only compound; not for human use.
What is retatrutide's mechanism of action?
Retatrutide is mechanistically described as a triple hormone receptor agonist: a single peptide conjugated to a fatty diacid that activates the GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP components reduce food intake and improve insulin sensitivity; the glucagon receptor component is studied for increasing energy expenditure via thermogenesis (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037). The diacid acylation produces reversible albumin binding, giving a ~6-day half-life and enabling once-weekly dosing. At the molecular level, all three receptors are G-protein-coupled receptors (GPCRs) linked to cAMP signalling pathways.
What is the difference between retatrutide and semaglutide or tirzepatide?
The difference is receptor target count. Semaglutide is a mono-agonist (GLP-1 receptor only). Tirzepatide is a dual agonist (GIP + GLP-1 receptors). Retatrutide is a triple agonist (GIP + GLP-1 + glucagon receptors). The addition of the glucagon receptor arm is the key structural difference and is the proposed mechanistic reason for the larger weight changes in the Phase 2 trial (−24.2% at 12 mg, 48 weeks; Jastreboff et al., NEJM 2023) compared to published Phase 3 benchmarks for tirzepatide (~−22.5%) and semaglutide (~−14.9%). All are investigational or pharmaceutical agents — not direct comparisons for Titan's research-use-only product.
Why does retatrutide have a ~6-day half-life?
The ~6-day half-life is produced by the fatty diacid acylation — a long-chain diacid is conjugated to the peptide backbone. This chemical modification promotes reversible binding to serum albumin in circulation, which dramatically extends plasma residence time. An unmodified peptide of similar size would be cleared by the kidneys in minutes. The NEJM 2023 paper describes the pharmacokinetics as 'dose-proportional' with a half-life of approximately 6 days. This is the same albumin-binding extension strategy used in semaglutide and is what enables once-weekly subcutaneous administration.
What does the glucagon receptor arm of retatrutide do?
The glucagon receptor (GCGR) arm is the energy-expenditure component of retatrutide's mechanism — distinct from the appetite-suppression effects of the GLP-1 and GIP arms. Glucagon receptor agonism is studied for stimulating thermogenesis in brown adipose tissue and increasing resting metabolic rate in humans (reviewed in Conceição-Furber et al., Front. Endocrinol. 2022;13:868037, doi: 10.3389/fendo.2022.868037). In the triple-agonist design, the GCGR arm is intended to complement reduced caloric intake with increased caloric expenditure — a dual mechanism not achievable with GLP-1 or GIP/GLP-1 alone. The relative contribution of each arm to the overall weight reduction seen in the NEJM 2023 trial remains an active area of study.
Is retatrutide approved or just investigational?
As of 2026, retatrutide (LY3437943) remains an investigational compound. Only Phase 2 data have been published (Jastreboff et al., NEJM 2023); Phase 3 trials are underway. It is not FDA-approved for any indication. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory use — not for human or animal administration. The clinical trial data described on this page is published science that informs the pharmacological context; it is not a claim about what Titan's product does, and it is not medical advice.

Related reading

Before you check out.